PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.19. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
-4.44
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of -0.83. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-5.44
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.54
Current ratio 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 2.06. Philip Fisher would check if strong liquidity supports growth investments.
68.40%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.85%. Michael Burry would check for aggressive accounting and hidden risks.